Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7561011 | 0.82 | KMT2A (0.46) | NPC1RAB9APKMMTNR1AMTNR1B | |
| SCHEMBL7560685 | 0.79 | CDC25B (0.52) | NPC1RAB9AKMT2AMEN1L3MBTL1 | |
| SCHEMBL12812906 | 0.77 | LMNA (0.56) | KMT2AMEN1L3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL12812726 | 0.76 | KMT2A (0.64) | NPC1RAB9APKMKMT2AMEN1 | |
| SCHEMBL7560911 | 0.76 | MTNR1A (0.48) | NPC1RAB9APKMMTNR1AMTNR1B | |
| SCHEMBL7564684 | 0.75 | PLK1 (0.55) | RAB9APKMKMT2AMEN1L3MBTL1 | |
| SCHEMBL1938499 | 0.74 | SMN1; SMN2 (0.55) | KMT2AMEN1L3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL27996446 | 0.72 | HTT (0.58) | NPC1RAB9AKMT2AMEN1LMNA | |
| SCHEMBL10243339 | 0.70 | LMNA (0.71) | NPC1RAB9AKMT2AMEN1L3MBTL1 | |
| SCHEMBL13055383 | 0.70 | LMNA (0.80) | NPC1RAB9AKMT2AMEN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020052354-A1 | Paramagnetic DOTA derivatives, pharmaceutical agents that contain the latter, process for their production, and their use for MR imaging of necrosis and infarction | SCHERING AG | 2002-05-02 | — | — | US | disclosed |
| WO-2001051095-A2 | PARAMAGNETIC DOTA DERIVATIVES, PHARMACEUTICAL AGENTS CONTAINING THE SAME, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE FOR THE MR IMAGING OF NECROSIS AND INFARCTION | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052354-A1 | Paramagnetic DOTA derivatives, pharmaceutical agents that contain the latter, process for their production, and their use for MR imaging of necrosis and infarction | TNNI3, NPR1, LPXN | NPC1 942/4885RAB9A 2331/4885PKM 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.